Clinical Trial Update: Natural Killer(NK) Cell Therapy for AML Minimal Residual Disease [Phase 1]

View source ↗

Summary

Phase 1 trial of natural killer cell therapy for acute myeloid leukemia presenting minimal residual disease has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Natural Killer cell therapy (natural killer cell therapy)

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: Minimal Residual Disease | Phase 1 | Status: TERMINATED